Compare TRVI & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRVI | BSTZ |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2019 | N/A |
| Metric | TRVI | BSTZ |
|---|---|---|
| Price | $13.31 | $23.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $28.18 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 191.0K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | ★ 31.91 | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.82 | $20.69 |
| 52 Week High | $20.22 | $31.89 |
| Indicator | TRVI | BSTZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 33.08 |
| Support Level | $13.00 | $22.95 |
| Resistance Level | $13.55 | $31.59 |
| Average True Range (ATR) | 0.88 | 0.92 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 20.92 | 6.50 |
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
BlackRock Science and Technology Trust II is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income mainly through long-term capital appreciation. The Trust invests a majority of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement, and use of science and/or technology. Its investment portfolio comprises securities of companies from various industries, such as semiconductors and semiconductor equipment, software, communications equipment, IT services, and entertainment, etc.